# US 7,745,606 B2 · Immunostimulatory sequence oligonucleotides and methods of using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,606 B2
- Document ID: US7745606B2
- Status: Granted
- Kind: B2
- Application number: 10/741,720
- Filed: 2003-12-18
- Published: 2006-03-16
- Granted: 2010-06-29
- Earliest claimed: 2002-12-23
- Assignees: Dynavax Technologies Corporation
- Inventors: Dino Dina; Karen L. Fearon; Jason Marshall
- Web page: https://patentgrep.com/patent/US7745606B2

## CPC

- C12N 15/117: Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 27/02: Ophthalmic agents
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 33/00: Antiparasitic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H 21/02: with ribosyl as saccharide radical
- C07H 21/04: with deoxyribosyl as saccharide radical
- C12N 2310/17: Immunomodulatory nucleic acids
- C12N 2310/315: Phosphorothioates
- C12N 2310/333: Modified A
- C12N 2310/336: Modified G
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides.

## Claims

### Claim 1

An isolated polynucleotide consisting essentially of: 5′TCGAACGTTCGAAGATGATGAT-3′ (SEQ ID NO: 171).

### Claim 2 (depends on 1)

A method of modulating an immune response in an individual comprising administering to an individual an immunomodulatory polynucleotide according to claim 1 in an amount sufficient to modulate an immune response in said individual.

### Claim 3 (depends on 1)

A method of increasing interferon-gamma (IFN-γ) in an individual, comprising: administering an immunomodulatory polynucleotide according to according to claim 1 to said individual in an amount sufficient to increase IFN-γ in said individual.

### Claim 4 (depends on 1)

A method of increasing interferon-alpha (IFN-α) in an individual, comprising: administering an immunomodulatory polynucleotide according to claim 1 to said individual in an amount sufficient to increase IFN-α in said individual.

### Claim 5 (depends on 1)

A method of ameliorating a symptom of an infectious disease in an individual, comprising: administering an effective amount of an immunomodulatory polynucleotide according to claim 1 to the individual, wherein an effective amount is an amount sufficient to ameliorate a symptom of said infectious disease.

### Claim 6 (depends on 1)

A method of ameliorating a symptom of an IgE-related disorder in an individual, comprising: administering an effective amount of an immunomodulatory polynucleotide according to claim 1 to an individual having an IgE-related disorder, wherein an effective amount is an amount sufficient to ameliorate a symptom of said IgE-related disorder.

### Claim 7 (depends on 1)

The isolated polynucleotide of claim 1 wherein polynucleotide comprises at least one phosphorothiorate linkage.

### Claim 8 (depends on 7)

The isolated polynucleotide of claim 7 wherein all the nucleotide linkages are phosphorothiorate linkages.

### Claim 9 (depends on 8)

The isolated polynucleotide of claim 8 wherein the polynucleotide consists of the sequence 5′-TCGAACGTTCGAAGATGATGAT-3′ (SEQ ID NO: 171).

### Claim 10 (depends on 1)

The isolated polynucleotide of claim 1 wherein the polynucleotide consists of the sequence 5′-TCGAACGTTCGAAGATGATGAT-3′ (SEQ ID NO: 171).